A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
By P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Bécette, S. André, M. Piccart, Mario Campone, E. Brain and 10 more. Nature Medicine, 2009
628 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/8186cf367f55fb6cb251083eccdbe0b4fcadebdf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Oncology
Citations in the corpus
- Stromal biology and therapy in pancreatic cancer (2010, background): “However, the pathophysiological mechanisms of tumour stromal signalling and its contribution to tumour progression and therapeutic resistance are still poorly understood in pancreatic cancer and other solid carcinomas.”
- Identification of tumor epithelium and stroma in tissue microarrays using texture analysis (2012, background): “Stromal cells and their roles in cancer prognosis [8] and response-prediction [9] have been increasingly recognized.”
- Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients (2014, neutral): “In breast cancer, mammary Epi cells can adopt a stromal gene expression pattern indistinguishable from reactive stroma when undergoing EMT (Farmer et al , 2009).”
- GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, neutral): “A multitude of microarray-based gene signatures have been derived stratifying breast cancer into subtypes [1,2,24], identifying patients at risk [5,6,8,9,11,12], and predicting response to therapeutic agents [3,4].”
- Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer (2010, methodology): “We evaluated the capability of the two genes to predict pCR by measuring the area under receiver operator characteristic (ROC) curv”
- Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854) (2013, background): “Indeed, a gene expression array of stroma cells has proven to have a predictive effect, which was also associated with the amount of stroma [28].”
- Dynamic EMT: a multi‐tool for tumor progression (2021, neutral): “In F9 teratocarcinoma, NMuMG cells and hepatocellular carcinoma (HCC), intratumoral or cocultured macrophages are secreting TGF b to promote EMT (Bonde et al , 2012; Fan et al , 2014).”
- Epithelial–mesenchymal transition in tumor metastasis (2016, background): “Finally, expression of EMT-TFs has been correlated negatively with pathologic response to treatment, suggesting a role in chemoresistance (Creighton et al., 2009; Farmer et al., 2009).”
- Fibroblast heterogeneity in the cancer wound (2014, background): “Evidence for the clinical relevance of CAFs came from a study by Farmer et al. (2009), who found that breast cancer patients responded poorly to neoadjuvant chemotherapy if their tumors had increased expression of stromal genes.”
- Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression (2011, background): “With this strategy, they identified a stromal signature where increased expression of stromal genes predicted patient response to neoadjuvant treatment with 5-fluorouracil, epirubicin and cyclophosphamid”
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes (2010, background): “Recent reports have linked expression of specific sets of genes to resistance to chemotherapy in breast cancer patients (52, 53).”
- Stroma Cells in Tumor Microenvironment and Breast Cancer (2012, neutral): “[94] reported that a 50-gene signature predicts poor response to anthracycline-based neoadjuvant chemotherapy (5-fluoro-”